Research dosing & reconstitution reference
Updated June 2026Precise peptide protocols, reconstitution math, and stack guides.
An instrument-grade reference for 38 research peptides — dose ranges, titration schedules, half-lives, and worked reconstitution tables, cross-referenced with clinical trials and community protocols. Every figure is sourced or flagged.
49 protocols & stacks indexed
Featured research supplier
Dynotides
Our reference partner for laboratory-grade research compounds. Each listing pairs a certificate of analysis (third-party HPLC/MS) with batch purity data so you can match a protocol on this site to a verified vial.
- Third-party COA (HPLC + mass-spec) per batch
- Reconstitution-ready vial sizes that match our calculators
- Cold-chain handling on temperature-sensitive peptides
Research discount code
Apply PROTOCOL at checkout on the partner shop for a research-buyer discount.
Browse by research goal
Eight categories of research compounds
Jump to the protocols grouped by what they're studied for.
Weight Loss / Metabolic
Incretins, amylin analogs & metabolic agents
Tissue Repair
Healing, tendon, ligament & gut lining
GH Optimization
GHRH analogs & growth-hormone secretagogues
Skin / Anti-Aging
Copper peptides, collagen & antioxidant signaling
Cognitive
Nootropic & neuroregulatory peptides
Longevity
Mitochondrial, senolytic & bioregulator peptides
Sexual / Hormonal
Melanocortin & reproductive-axis peptides
Anti-Inflammatory / Gut
Immune modulation & gut-barrier signaling
Quick reference
The full dosing table
Search, filter by category, and sort every catalogued compound by dose range, frequency, half-life, or route.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
38 of 38 compounds
| Source | ||||||
|---|---|---|---|---|---|---|
| 5-Amino-1MQ5-amino-1-methylquinolinium | Weight Loss / Metabolic | 50–150 mg daily (community) | Once daily (oral) | ~3.8 h (IV) to ~6.9 h (oral) in preclinical PK | Oral | Shop |
| AOD-9604HGH fragment 176-191 | Weight Loss / Metabolic | 250–500 mcg daily (community) | Once daily | Short, on the order of hours (rapidly cleared) | Subcutaneous | Shop |
| BPC-157Body Protection Compound 157 | Tissue Repair | 250–500 mcg daily | 1–2× daily | Very short in plasma (~15 min IV in rats; undetectable by ~4 h) | Subcutaneous (also studied oral) | Shop |
| CagrilintideAM833 | Weight Loss / Metabolic | 0.3–4.5 mg weekly | Once weekly | ~7–9 days (≈180 h) | Subcutaneous | Shop |
| CJC-1295 (no-DAC)Mod GRF 1-29 | GH Optimization | 100 mcg per dose (community) | 1–3× daily | ~30 minutes | Subcutaneous | Shop |
| CJC-1295 DACCJC-1295 with DAC | GH Optimization | ~1–2 mg weekly (community) | 1–2× weekly | ~6–8 days (DAC albumin binding) | Subcutaneous | Shop |
| DSIPDelta Sleep-Inducing Peptide | Cognitive | 100–300 mcg per dose (community); 25 nmol/kg IV in older trials | Once in the evening, 1–3 h before sleep | Very short in plasma (on the order of minutes) | Subcutaneous (intravenous in older clinical studies) | Shop |
| EpitalonEpithalon | Longevity | 5–10 mg per course day (community) | Short courses (10–20 days), repeated 2–3× per year | Very short — minutes in circulation, though gene-level effects are proposed to outlast it | Subcutaneous | Shop |
| FOXO4-DRIFOXO4-D-Retro-Inverso | Longevity | No established human dose; community ladders cite 250–500 mcg | Experimental (community ladders run in cycles) | Not well characterized; reportedly short and oxidation-sensitive | Subcutaneous (animal studies used intraperitoneal/IV) | Shop |
| GHK-CuCopper tripeptide-1 | Skin / Anti-Aging | 1–2 mg daily (SC) or topical | Daily | ~30–60 minutes (plasma) | Subcutaneous or topical | Shop |
| GHRP-6Growth Hormone Releasing Peptide-6 | GH Optimization | 100–300 mcg per dose (community) | 1–3× daily | ~2.5 h (elimination); ~8 min distribution | Subcutaneous | Shop |
| GlutathioneGSH | Skin / Anti-Aging | 500 mg/day oral (RCT); 600–1,200 mg/session IV (clinic) | Daily (oral) to 1–2× weekly (IV) | ~2–3 hours (plasma GSH) | Oral, IV, IM, SC, intranasal/nebulized | Shop |
| HumaninHN | Longevity | Community-dependent, mg-range SC (no validated human dose) | Roughly 1–3× weekly in cycles (community) | Native peptide ~30 min; the HNG analog was engineered to last longer | Subcutaneous | Shop |
| IGF-1 LR3Long R3 IGF-1 | GH Optimization | 20–100 mcg daily (community) | Once daily | ~20–30 hours | Subcutaneous | Shop |
| IpamorelinNNC 26-0161 | GH Optimization | 100–300 mcg per dose (community) | 1–3× daily | ~2 hours | Subcutaneous | Shop |
| KisspeptinKisspeptin-10 | Sexual / Hormonal | 50–200 mcg (KP-10, community); 1 nmol/kg/h IV (KP-54, trials) | Once daily pulse (community) or single trial infusion | KP-10 ~4 min; KP-54 ~28 min (subcutaneous) | Subcutaneous (intravenous in clinical trials) | Shop |
| KPVLys-Pro-Val | Anti-Inflammatory / Gut | 200–500 mcg daily (community) | 1–2× daily | Short (small tripeptide, rapidly cleared) | Subcutaneous (also oral for gut) | Shop |
| Melanotan IIMT-II | Sexual / Hormonal | 100 mcg–1 mg (community loading→maintenance) | Daily loading, then 1–2× weekly maintenance | ~1–2 hours (plasma) | Subcutaneous | Shop |
| Methylene BlueMethylthioninium chloride | Cognitive | Low-dose ~5–20 mg/day (community); 0.5–4 mg/kg single dose (research) | Daily (low-dose) — morning/early afternoon | Long, ~15 hours; cleared over roughly a day, mostly in urine | Oral (also 1 mg/kg IV for methemoglobinemia) | Shop |
| MOTS-cMitochondrial-derived peptide | Longevity | 5–10 mg per dose (community) | 2–3× weekly | Not well characterized in humans (short, typical of small peptides) | Subcutaneous | Shop |
| NAD+Nicotinamide adenine dinucleotide | Longevity | Wide range by route, e.g. 50–500 mg (community/clinic) | Daily to weekly | Short (intact NAD+ is rapidly metabolized in circulation) | IV (also subcutaneous) | Shop |
| OxytocinOXT | Sexual / Hormonal | 24 IU intranasal (research); 0.5–1 mU/min IV (obstetric label) | Per session (intranasal) or continuous infusion (obstetric) | Plasma ~3–6 min; central ~20 min after intranasal | Intranasal (research); intravenous/intramuscular (approved obstetric) | Shop |
| PinealonEDR peptide | Cognitive | 1–2 mg/day subcutaneous; 20 mg/day oral (community) | Once daily, in short courses | Not formally characterized; very short in plasma (typical of small peptides) | Subcutaneous (also oral capsules) | Shop |
| PT-141 (Bremelanotide)Bremelanotide | Sexual / Hormonal | 1.75 mg per dose (approved) | As needed (≤8/month) | ~2.7 hours (range 1.9–4.0 h) | Subcutaneous | Shop |
| RetatrutideLY3437943 | Weight Loss / Metabolic | 1–12 mg weekly (trial range) | Once weekly | ~6 days (≈144 h) | Subcutaneous | Shop |
| SelankTP-7 | Cognitive | 250–500 mcg per dose (community) | 1–2× daily | Very short in plasma (minutes); central effects outlast it | Intranasal | Shop |
| SemaglutideOzempic | Weight Loss / Metabolic | 0.25–2.4 mg weekly | Once weekly | ~7 days (≈165 h) | Subcutaneous | Shop |
| SemaxACTH(4-10) analog | Cognitive | 200–600 mcg per dose (community) | 1–2× daily | Very short in plasma (minutes); central effects outlast it | Intranasal | Shop |
| SermorelinGRF 1-29 | GH Optimization | 100–500 mcg daily (titrated) | Once daily (usually at bedtime) | ~11–12 minutes | Subcutaneous | Shop |
| SLU-PP-332pan-ERR agonist | Weight Loss / Metabolic | No established human dose (animal studies: ~25–50 mg/kg) | Varies (research; once or twice daily in animals) | Short — microsomal t½ ~31 minutes in vitro; not characterized in humans | Subcutaneous (research; injected intraperitoneally in animal studies) | Shop |
| SS-31Elamipretide | Longevity | 40 mg once daily subcutaneously in trials | Once daily (clinical-trial schedule) | Short (a few hours by subcutaneous route) | Subcutaneous | Shop |
| SurvodutideBI 456906 | Weight Loss / Metabolic | 0.6–4.8 mg weekly (trial range) | Once weekly | ~100 hours (supports once-weekly dosing) | Subcutaneous | Shop |
| TB-500Thymosin Beta-4 fragment | Tissue Repair | 2–2.5 mg twice weekly (loading), then weekly | 2× weekly then weekly | Plasma half-life on the order of hours; tissue effects reportedly persist days | Subcutaneous | Shop |
| TesamorelinEgrifta | GH Optimization | 2 mg daily (approved dose) | Once daily | ~26–38 minutes | Subcutaneous | Shop |
| TesofensineNS2330 | Weight Loss / Metabolic | 0.25–1 mg daily (trial range) | Once daily (oral) | ~9 days (~220 hours) | Oral | Shop |
| Thymosin Alpha-1Tα1 | Anti-Inflammatory / Gut | 1.6 mg per dose (typical Zadaxin) | 2× weekly (typical) | ~2 hours | Subcutaneous | Shop |
| TirzepatideMounjaro | Weight Loss / Metabolic | 2.5–15 mg weekly | Once weekly | ~5 days (≈117 h) | Subcutaneous | Shop |
| VIPVasoactive Intestinal Peptide | Anti-Inflammatory / Gut | 50 mcg/nostril intranasal (community); 50–200 mcg SC; IV aviptadil in trials | Intranasal up to 4× daily, or SC 1–2× daily (community) | Very short (~1–2 minutes in plasma) | Intranasal (community); intravenous as aviptadil in trials | Shop |
Reconstitution
Mix it once, measure it right
Turn a lyophilized vial into an exact syringe draw. The math is simple — the consequences of getting it wrong are not.
// worked example
concentration = 10 mg × 1000 / 2 mL = 5,000 mcg/mL
volume = 500 mcg / 5,000 = 0.1 mL
units = 0.1 mL × 100 = 10 units
At 5,000 micrograms per millilitre, a 500 microgram dose is 0.1 millilitres, or 10 units on a U-100 syringe, giving 20 doses per vial.
Combinations
Peptide stacks
Why compounds are combined, with separate-vial and pre-blended reconstitution math.
Wolverine (BPC-157 + TB-500)
The 'Wolverine' stack pairs two of the most widely discussed repair peptides because their proposed mechanisms are complementary rather than redundant. BPC-157 is associated with angiogenesis and localized tendon/ligament/gut signaling, while TB-500 (a synthetic fragment of thymosin beta-4) is associated with actin regulation and cell migration across tissue.
GLOW (BPC-157 + TB-500 + GHK-Cu)
GLOW extends the Wolverine repair pairing with GHK-Cu, a copper-binding tripeptide associated with collagen synthesis, skin remodeling, and wound cosmesis. The idea is to combine systemic/structural repair (BPC-157 + TB-500) with a skin- and collagen-oriented signal (GHK-Cu).
KLOW (KPV + BPC-157 + TB-500 + GHK-Cu)
KLOW adds KPV — a tripeptide fragment of alpha-MSH with anti-inflammatory properties — to the GLOW stack, aiming to pair tissue/skin repair with an inflammation- and gut-oriented signal.
CJC-1295 (no-DAC) + Ipamorelin
This is the classic growth-hormone-secretagogue pairing. CJC-1295 without DAC (a GHRH analog, also called Mod GRF 1-29) increases the amount of GH released per pulse, while Ipamorelin (a selective ghrelin-receptor agonist) triggers a clean GH pulse with minimal effect on cortisol or prolactin.
CagriSema (Cagrilintide + Semaglutide)
CagriSema combines a long-acting amylin analog (cagrilintide) with a GLP-1 agonist (semaglutide), each titrated toward 2.4 mg weekly. The two appetite mechanisms — amylin-mediated and GLP-1-mediated satiety — are additive, and the combination has advanced through Phase 3 (REDEFINE) as a fixed-dose product.
Russian Nootropic (Selank + Semax)
Selank and Semax are short peptides developed in Russia, where they are used clinically as nasal sprays. Selank is derived from tuftsin and associated with anxiolytic effects; Semax is an ACTH(4-10) fragment associated with focus and neuroprotection. Stacking them aims to pair calm (Selank) with drive/focus (Semax).
Editorial structure
What's in every protocol guide
Each fully written protocol follows the same 14-section template, so you always know where to look.
- 01
Overview & summary
What the compound is, what it's studied for, and the headline finding.
- 02
Key parameters
Dose range, frequency, half-life, route, vial sizes, and regulatory status at a glance.
- 03
Mechanism of action
The receptors and pathways involved, in plain language.
- 04
Dosing protocol & phases
Titration, maintenance, and any loading phases with week ranges.
- 05
Reconstitution guide
Worked dose→volume tables for common vial and water combinations.
- 06
Interactive calculator
A live calculator pre-filled with that compound's vial sizes.
- 07
Missed-dose guidance
What published labels or protocols say about a skipped dose.
- 08
Side effects & safety
Reported adverse effects, with trial incidence where it exists.
- 09
Clinical trials & evidence
Key studies, phases, populations, results, and trial identifiers.
- 10
Storage & handling
Stability of the lyophilized powder and the reconstituted solution.
- 11
Comparisons
Side-by-side against related compounds across target, half-life, and efficacy.
- 12
Related stacks
Combinations that feature the compound and why.
- 13
Sources & references
Citations to PubMed, NEJM, Lancet, and ClinicalTrials.gov.
- 14
FAQ
Common questions, marked up with FAQ structured data.
Directory
A–Z index
Every catalogued compound, alphabetically. Jump by letter.
A
- AOD-9604Weight
B
- BPC-157Tissue
C
D
- DSIPCognitive
E
- EpitalonLongevity
F
- FOXO4-DRILongevity
G
- GHK-CuSkin
- GHRP-6GH
- GlutathioneSkin
H
- HumaninLongevity
I
K
- KisspeptinSexual
- KPVAnti-Inflammatory
M
- Melanotan IISexual
- Methylene BlueCognitive
- MOTS-cLongevity
N
- NAD+Longevity
O
- OxytocinSexual
P
- PinealonCognitive
- PT-141 (Bremelanotide)Sexual
R
- RetatrutideWeight
S
- SelankCognitive
- SemaglutideWeight
- SemaxCognitive
- SermorelinGH
- SLU-PP-332Weight
- SS-31Longevity
- SurvodutideWeight
T
- TB-500Tissue
- TesamorelinGH
- TesofensineWeight
- Thymosin Alpha-1Anti-Inflammatory
- TirzepatideWeight
V
- VIPAnti-Inflammatory
#
- 5-Amino-1MQWeight
Questions
Frequently asked questions
Is anything on this site medical advice?
No. The Peptide Protocol Index is an educational and research reference. Nothing here is medical advice, and the compounds discussed are framed for laboratory research use only — not for human consumption. Always consult a qualified professional before making any health decision.
How is reconstitution math calculated?
Concentration (mcg/mL) equals vial mass in milligrams times 1000, divided by the millilitres of bacteriostatic water added. The draw volume equals your target dose in micrograms divided by that concentration, and U-100 syringe units equal the draw volume in millilitres times 100. Our calculator does this live and flags doses that are too small to measure or too large to fit a syringe.
What does the 'Needs verification' badge mean?
Some protocols are structural scaffolds: the framework and core parameters are in place, but specific figures (such as trial percentages) have not yet been confirmed against primary sources. Those entries are clearly flagged so figures are never mistaken for verified data.
Where do the dosing figures come from?
Fully written protocols cite published clinical trials and regulatory labels. Where only community or anecdotal dosing exists — common for research-only peptides — it is labeled as community-derived. We never invent trial percentages; unverified figures are marked rather than guessed.
What is the difference between a protocol and a stack?
A protocol covers a single compound in depth. A stack is a combination of two or more compounds run together, with the rationale for combining them plus separate-vial and pre-blended reconstitution math.
Are these compounds approved or legal?
It varies by compound and jurisdiction. Some are FDA-approved drugs, some are approved abroad, and many are investigational or research-only. Regulatory status is listed on each protocol page. Research compounds are not approved for human use; verify the law in your location.